TY -的A2 Cantara西尔维亚盟——张Wu-wen盟——明Xin-liang盟——荣元盟——黄Chao-qun AU -翁,香港非盟-陈郝盟——扁Jun-mei AU - Wang Fu-bing PY - 2019 DA - 2019/12/16 TI -诊断价值的调查和生物信息学分析miR-31患者淋巴结转移的结直肠癌SP - 9740475六世- 2019 AB -结直肠癌(CRC)是最常见的癌症之一,发生在发达国家。遥远的CRC转移导致超过90%的CRC-associated死亡率。小分子核糖核酸(microrna)起着关键的作用在调节肿瘤转移和可能潜在的CRC患者诊断的生物标志物。本研究旨在识别可以作为诊断生物标记的microrna CRC转移。朝着这个目标,我们比较五个microrna的表达通常与转移有关(即。miR-10b mir - 200 c, mir - 155, miR-21和miR-31)之间主要CRC (pCRC)相应组织和转移性淋巴结(mCRC)。此外,生物信息学分析miR-31进行预测目标基因和相关信号通路。结果表明miR-31、miR-21 miR-10b, mir - 155表达不同程度的增加,而mir - 200 - c表达式是比pCRC mCRC低。此外,我们发现miR-31和miR-21水平明显增加pCRC当淋巴结转移(LNM),和增加miR-31表达更深刻。因此,调节miR-31和miR-21表达可能在CRC microrna的签名转移。 Moreover, we detected a higher miR-31 level in the plasma of CRC patients with LNM compared to patients without LNM or healthy individuals. With the bioinformatics analysis of miR-31, 121 putative target genes and transition of mitotic cell cycle and Wnt signaling pathway were identified to possibly play a role in CRC progression. We next identified seven hub genes via module analysis; of these, TNS1 was most likely to be the target of miR-31 and had significant prognostic value for CRC patients. In conclusion, miR-31 is significantly increased in the cancer tissues and plasma of CRC patients with LNM; thus, a high level of miR-31 in the plasma is a potential biomarker for the diagnosis of LNM of CRC. SN - 2210-7177 UR - https://doi.org/10.1155/2019/9740475 DO - 10.1155/2019/9740475 JF - Analytical Cellular Pathology PB - Hindawi KW - ER -